Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...

Regeneron Pharmaceuticals Inc. REGN shares are trading higher on Wednesday, recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat.

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

Regeneron Q1 EPS fell 14% to $8.22, missing estimates; revenue dropped 4% to $3.03 billion, also below consensus. Eylea sales fell 26% to $1.04 billion amid pricing pressure and market share loss ...

Regeneron Pharmaceuticals (REGN) shares sank when the biopharma firm's earnings and revenue missed forecasts as sales of its blockbuster eye treatment, Eylea, were weaker than anticipated.

Regeneron faced mixed results in Q1 2025 with challenges in its retinal franchise offset by strong pipeline progress and Dupixent’s robust performance. The company remains focused on resolving ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Zoho co-founder Sridhar Vembu has dropped his ambitious semiconductor fab investment plan stating it was too capital-intensive and did not have the confidence in the tech. The company - Silectric ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Neutral to Buy. As of May 6, 2025, the average one-year price target for ...